Current Programs
MPCCC’s mission is to improve cancer outcomes for all through equitable access to precision oncology, clinical trials and high quality, coordinated cancer care.

Precision Oncology
We aim to advance equitable access to precision oncology, genomics and research-based cancer care across metropolitan, regional and rural Victoria.
The advancement of research and genomic testing are transforming cancer care. Precision oncology uses genetic information to identify targeted treatments and offers more personalised cancer treatment. However, equitable access to precision oncology expertise, clinical trials and innovative therapies remains inconsistent across Victoria.
Equitable access to genomic testing
Our work is focused on improving access to genomic testing and strengthening the pathway from testing to clinical decision-making. By strengthening coordinated referral pathways across the MPCCC network, we support timely referral of eligible patients to genomic testing. Through awareness roadshows at hospitals and educational resources, we increase the understanding of health professionals on cancer genomics and precision oncology.
Working in partnership with health services, research organisations and other key stakeholders, we are expanding access to comprehensive genomic profiling (CGP) so that more Victorians living with cancer can benefit from advances in precision oncology, regardless of where they receive care.
MPCCC Molecular Tumour Boards
Since 2018, MPCCC hosts regular Molecular Tumour Boards (MTBs) which bring together multidisciplinary experts to support the interpretation of complex genomic reports, and identify potential personalised treatments and clinical trials informed by an individual’s genomic and clinical information. The MTBs are well attended by oncologists, physician scientists, researchers, pathologists, clinical geneticists, clinical trials coordinators, and key subject matter experts.
This allows knowledge and information exchange between health professionals across different health services, and improves patient outcomes through access to targeted treatments and potentially clinical trials - especially for individuals with complex, advanced and treatment-resistant cancers.
Clinicians are welcome to refer patients and join our MTB meetings. For more information, please email: mpccc-mtbcoordinator@monash.edu.
Our Impact as of April 2026:

